The market for biologic therapeutic drugs and therapeutic proteins was worth $93.14 billion in 2018 and is expected to reach $93.14 billion by 20221 It will nearly double by the end of the year. However, the selection of high-yield mammalian CHO cell lines still represents a major bottleneck in the development of biopharmaceutical production processes2Therefore, developing new high-throughput methods to select highly expressed CHO cell lines in an effective and cost-effective manner has become increasingly important. The traditional methods of gene amplification and limited dilution induced by multiple rounds of methotrexate (MTX) or methionine sulfoxide imine (MSX) are inefficient, time-consuming, laborious, and do not always produce clones with the required production levels. The screening method of FACS can improve efficiency and throughput, but it requires a large amount of capital investment, intensive operator training, and specialized personnel. The FACS workflow is susceptible to cross contamination due to non disposable components in direct contact with cells. In addition, for cell lines sensitive to fluid pressure, cells may exhibit lower viability and may not recover well after FACs screening.